A group of more than 100 leading cancer experts are supporting a patient-based grassroots movement demanding action on the high price of cancer drugs--see petition at end of blog to participate.
Tefferi blames drug company greed, physicians who are too quick to prescribe new drugs without proven efficacy, health insurers willing to go along with upwards of $3,000-a-month co-pays, and a lack of federal government oversight adding checks and balances to a Wild West of drug pricing — especially for the federal health plan for seniors, Medicare, which is barred from negotiating drug prices. That prohibition was signed into law by President George W. Bush in 2003.
Dataset for Pricing in the Market for Anticancer Drugs
Here is a dataset from "Pricing in the Market for Anticancer Drugs."Journal of Economic Perspectives: Vol. 29 No. 1 (Winter 2015). Download this guide to the dataset to help guide analyses.
How did this happen? Under the Influence CBS News
Thoughtful discussions about content development and outcomes analytics that apply the principles and frameworks of health policy and economics to persistent and perplexing health and health care problems
Bonny is a data enthusiast applying curated analysis and visualization to persistent tensions between health policy, economics, and clinical research in oncology.